TRV-120027 TFA|西域试剂

TRV-120027 TFA,98.34%

产品编号：Bellancom-P2141A| 分子式：C₄₅H₆₈F₃N₁₃O₁₂| 分子量：1040.10

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P2141A	￥750.00	杭州北京（现货）
Bellancom-P2141A	￥2200.00	杭州北京（现货）
Bellancom-P2141A	￥3500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

TRV-120027 TFA

产品介绍

TRV120027 TFA 是血管紧张素 II 受体 1 型 (AT1R) 的 β-arrestin-1 激动剂。TRV120027 TFA 通过阳离子通道亚家族 C3 (TRPC3) 偶联诱导急性儿茶酚胺分泌，促进质膜上 AT1R-β-arrestin-1-TRPC3-PLCγ形成大分子复合物。TRV120027 TFA 抑制血管紧张素 II 介导的血管收缩并增加心肌细胞的收缩力。TRV120027 TFA有潜力用于急性失代偿性心力衰竭 (ADHF) 的研究。

生物活性

TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling. TRV120027 TFA induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the acute decompensated heart failure (ADHF) treatment.

体外研究

TRV120027 TFA (100 nM) significantly increases the AT1R and TRPC3 association with the immunoprecipitated β-arrestin-1 in HEK293 cells co-transfected with Flag-AT1R-cherry, HA-β-arrestin-1 and TRPC3-GFP.
TRV120027 TFA (100 nM) induces an [Ca²⁺]i increase in HEK293 cells co-transfected with AT1R, β-arrestin-1, and TRPC3, which are significantly blocked by Pyr3 pre-incubation in HEK293 cells co-transfected with Flag-AT1R-Cherry, HA-β-arrestin-1, and TRPC3-GFP.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

TRV120027 TFA (intravenous injection; 0.3 or 1.5 µg/kg per minute; infusion rate, 0.5 mL/min) when added to furosemide decreases cardiac preload and afterload, systemic and renal vascular resistances, and left ventricular external work while increasing cardiac output and renal blood flow. GFR and renal excretory function are maintained in canines with experimental HF.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male mongrel dogs (weight, 20.5–30 kg)
Dosage:	0.3 or 1.5 µg/kg per minute; infusion rate, 0.5 mL/min
Administration:	Intravenous injection
Result:	Resulted in dose-dependent vasodilation, increased cardiac contractility, and decreased myocardial oxygen consumption in dog.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male mongrel dogs (weight, 20.5–30 kg)
Dosage:	0.3 or 1.5 µg/kg per minute; infusion rate, 0.5 mL/min
Administration:	Intravenous injection
Result:	Resulted in dose-dependent vasodilation, increased cardiac contractility, and decreased myocardial oxygen consumption in dog.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (96.14 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.9614 mL	4.8072 mL	9.6145 mL
5 mM	0.1923 mL	0.9614 mL	1.9229 mL
10 mM	0.0961 mL	0.4807 mL	0.9614 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (2.40 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.40 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (2.40 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.40 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (2.40 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (2.40 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。